Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: J Surg Oncol. 2020 Jul 1;122(5):869–876. doi: 10.1002/jso.26077

Table I.

Patient Demographics

AWD DOD NED
Age
Average 52.9 ± 20.3 61.9 ± 14.1 58.2 ± 21.9
Sex
Female 3 (23.1%) 14 (41.2%) 19 (45.2%)
Male 10 (76.9%) 20 (58.8%) 23 (54.8%)
Ethnicity
African American 3 (23.1%) 14 (41.2%) 19 (45.2%)
Asian 10 (76.9%) 20 (58.8%) 23 (54.8%)
Caucasian 6 (46.2%) 21 (61.8%) 31 (73.8%)
Hispanic or Latino 3 (23.1%) 4 (8.8%) 5 (11.9%)
Other 2 (15.4%) 5 (14.7%) 3 (7.1%)
Charlson-Deyo Score
0 7 (53.8%) 23 (67.6%) 27 (64.3%)
1 5 (38.5%) 7 (20.6%) 8 (19%)
2 1 (7.7%) 4 (11.8%) 7 (16.7%)
Tumor Location
Extremity 12 (92.3%) 26 (76.5%) 36 (85.7%)
Trunk 1 (7.7%) 8 (23.5%) 6 (14.3%)
Tumor Size
≤ 10 cm in greatest dimension 4 (30.8%) 19 (55.9%) 32 (76.2%)
>10 cm in greatest dimension 9 (69.2%) 15 (44.1%) 10 (23.8%)
Tumor Grade
2 2 (15.4%) 2 (5.9%) 5 (11.9%)
3 11 (84.6%) 32 (94.1%) 37 (88.1%)
Tumor Stage
II 1 (7.7%) 3 (8.8%) 16 (38.1%)
IIIA 3 (23.1%) 15 (44.1%) 16 (38.1%)
IIIB 6 (46.2%) 10 (29.4%) 10 (23.8%)
IV 3 (23.1%) 6 (17.6%) 0 (0%)
Surgical Margins
Negative 10 (76.9%) 29 (85.3%) 39 (92.9%)
Positive 3 (23.1%) 5 (14.7%) 3 (7.1%)
Tumor Pre-Op Treatment
Both 2 (15.4%) 8 (23.5%) 8 (19%)
Chemo 2 (15.4%) 1 (2.9%) 2 (4.8%)
None 5 (38.5%) 11 (32.4%) 15 (35.7%)
RT 4 (30.8%) 14 (41.2%) 17 (40.5%)
Tumor Post-Op Treatment
Both 3 (23.1%) 4 (11.8%) 2 (4.8%)
Chemo 5 (38.5%) 13 (38.2%) 4 (9.5%)
None 3 (23.1%) 11 (32.4%) 31 (73.8%)
RT 2 (15.4%) 6 (17.6%) 5 (11.9%)
Length of Follow-Up
Average 31.96 ± 19.23 23.53 ± 18.63 50.21 ± 29.13
PACS SMD (HU)
Average 37.3±16.6 34.2±13.2 41.2±13.2
PACS SMI (cm2/m2)
Average 4.9±1.5 4.5±1.3 4.4±1.3
OsiriX SMD (HU)
Average 39.4 ± 15.9 36.9 ± 12.9 43.7 ± 12.8
OsiriX SMI (cm2/m2)
Average 3.9 ± 1.2 3.9 ± 2.0 3.5± 1.2